Tenofovir alafenamide significantly increased serum lipid levels compared with entecavir therapy in chronic hepatitis B virus patients.

Rui-Min Lai,Shan Lin,Miao-Miao Wang,Na Li, Jia-Hui Zhou,Xiao-Yu Lin,Tian-Bin Chen,Yue-Yong Zhu,Qi Zheng

World journal of hepatology（2023）

引用 0|浏览5

暂无评分

摘要

A greater increase in TCHO was observed in patients with CHB receiving TAF compared to those receiving ETV. However, TAF-induced dyslipidemia did not increase the incidence of NAFLD.

查看译文

关键词

Tenofovir alafenamide, Entecavir, Hepatitis B virus, Serum lipid, Metabolic factor

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要